申请人:Rxbio, Inc.
公开号:EP2767541A1
公开(公告)日:2014-08-20
Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including treating cancer, producing radioprotection and/or radiomitigation, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.
公开了根据式(I)的化合物以及包括这些化合物的药物组合物。还公开了使用这些化合物的方法,这些化合物具有作为 LPA 受体的激动剂或拮抗剂的活性;这些方法包括治疗癌症、产生辐射防护和/或辐射缓解、增强细胞增殖、治疗伤口、治疗细胞凋亡或保存或恢复细胞、组织或器官的功能、培养细胞、保存器官或组织功能以及治疗皮肤病。